The EMA's Emergency Task Force (ETF) is improving its approach to scientific advice for medicines and vaccines being developed in the context of threats to public health, including antimicrobial resistance.1 The new approach provides developers with clear information on the design of clinical trials, enabling them to obtain the appropriate evidence needed to approve medicines.1 The advice focuses on how clinical trials should be structured and conducted during the development of new therapies.[This approach is essential for improving the rapid development and approval of medicines before and during public health emergencies.1 The aim is to ensure alignment between developers and regulators in the development of critical medicines.1 The ETF builds on lessons learned from previous emergencies and offers scientific support to facilitate clinical trials.